Immatics Biotechnologies Gmbh

Ludwig Institute for Cancer Research Limited

Stefan Stevanovic

Toni Weinschenk

Ugur Sahin

Daniel Johannes Kowalewski

Lloyd J Old

Hans-Georg Rammensee

Ozlem Tureci

Yao-tseng Chen

Moreno Di Marco

Annika Nelde

Markus Loeffler

Claudia Berlin

Peter Lewandrowski

Michael Pfreundschuh

Claudia Trautwein

Ali O Gure

Juliane Sarah Walz

Hans Georg Rammensee

Nico Trautwein

Sebastian Haen

Juliane Stickel

Simon Walz

Cecile Gouttefangeas

Hans-Goerg Rammensee

Claudia Lemmel

Cécile Gouttefanges

Peter Brossart

Wolfram Brugger

Lothar Kanz

Markus Löffler

Michael Pfreudschuh

Frank Neumann

Hans-George Rammensee

Hans-georg Rammensee

Georg Rammensee

The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Powerful MHC-class II peptides derived from survivin

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers

Peptides and combination thereof for use in the immunotherapy against cancers

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

Growing community of inventors

Tuebingen, Germany

Stefan Stevanovic